MIR-133A IS A PREDICTIVE BIOMARKER IN PATIENTS WITH METASTATIC COLORECTAL CANCER RECEIVING OXALIPLATIN-BASED CHEMOTHERAPY

被引：0
|
作者：
Ng, Simon S.
Dong, Yujuan
Leung, Wing Wa
Ma, Brigette B.
To, Ka Fai
Sung, Joseph J.
Yu, Jun
机构：
来源：
GASTROENTEROLOGY | 2018年 / 154卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
374
引用
收藏
页码：S88 / S88
页数：1
相关论文
共 50 条
  • [41] miR-124 Intensified Oxaliplatin-Based Chemotherapy by Targeting CAPN2 in Colorectal Cancer
    Xie, Xu-Qin
    Wang, Mo-Jin
    Li, Yuan
    Lei, Lin-Ping
    Wang, Ning
    Lv, Zhao-Ying
    Chen, Ke-Ling
    Zhou, Bin
    Ping, Jie
    Zhou, Zong-Guang
    Sun, Xiao-Feng
    MOLECULAR THERAPY-ONCOLYTICS, 2020, 17 : 320 - 331
  • [42] CAPECITABINE AND OXALIPLATIN (CAPOX) PLUS CETUXIMAB IN PATIENTS WITH METASTATIC COLORECTAL CARCINOMA WHO PROGRESSED AFTER OXALIPLATIN-BASED CHEMOTHERAPY
    Petrovic, Z.
    ANNALS OF ONCOLOGY, 2008, 19 : 135 - 135
  • [43] Tumor Suppressor Functions of miR-133a in Colorectal Cancer
    Dong, Yujuan
    Zhao, Junhong
    Wu, Chung-Wah
    Zhang, Lijing
    Liu, Xiaodong
    Kang, Wei
    Leung, Wing-Wah
    Zhang, Ning
    Chan, Francis K. L.
    Sung, Joseph J. Y.
    Ng, Simon S. M.
    Yu, Jun
    MOLECULAR CANCER RESEARCH, 2013, 11 (09) : 1051 - 1060
  • [44] Bimonthly Chemotherapy with Oxaliplatin, Irinotecan, Infusional 5-Fluorouracil/Folinic Acid in Patients with Metastatic Colorectal Cancer Pretreated with Irinotecan- or Oxaliplatin-Based Chemotherapy
    Nobili, S.
    Checcacci, D.
    Filippelli, F.
    Del Buono, S.
    Mazzocchi, V.
    Mazzei, T.
    Mini, E.
    JOURNAL OF CHEMOTHERAPY, 2008, 20 (05) : 622 - 631
  • [45] Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy
    Souglakos, J.
    Kalykaki, A.
    Vamvakas, L.
    Androulakis, N.
    Kalbakis, K.
    Agelaki, S.
    Vardakis, N.
    Tzardi, M.
    Kotsakis, A. P.
    Gioulbasanis, J.
    Tsetis, D.
    Sfakiotaki, G.
    Chatzidaki, D.
    Mavroudis, D.
    Georgoulias, V.
    ANNALS OF ONCOLOGY, 2007, 18 (02) : 305 - 310
  • [46] The impact of oxaliplatin-based chemotherapy for colorectal cancer on the autonomous nervous system
    Dermitzakis, E. V.
    Kimiskidis, V. K.
    Eleftheraki, A.
    Lazaridis, G.
    Konstantis, A.
    Basdanis, G.
    Tsiptsios, I.
    Georgiadis, G.
    Fountzilas, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 (12) : 1471 - 1477
  • [47] Oxaliplatin-Based Chemotherapy for Colon Cancer
    Bonetti, Andrea
    Furini, Lara
    PLATINUM AND OTHER HEAVY METAL COMPOUNDS IN CANCER CHEMOTHERAPY: MOLECULAR MECHANISMS AND CLINICAL APPLICATIONS, 2009, : 271 - 284
  • [48] Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment
    Kjersem, J. B.
    Ikdahl, T.
    Lingjaerde, O. C.
    Guren, T.
    Tveit, K. M.
    Kure, E. H.
    MOLECULAR ONCOLOGY, 2014, 8 (01) : 59 - 67
  • [49] ERCC1 and the Prognosis for Patients With Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy
    Baek, Moo-Jun
    ANNALS OF COLOPROCTOLOGY, 2015, 31 (03) : 81 - 81
  • [50] Spleen Volume as a Predictive Biomarker for Thrombocytopenia and Liver Dysfunction After Oxaliplatin-based Chemotherapy
    Miyata, Takashi
    Takamura, Hiroyuki
    Kin, Ryosuke
    Nishiki, Hisashi
    Hashimoto, Akifumi
    Fujii, Yoritaka
    Miura, Seiko
    Fujita, Jun
    Kaida, Daisuke
    Tomita, Yasuto
    Nakamura, Naohiko
    Fujita, Hideto
    Kinami, Shinichi
    Ueda, Nobuhiko
    Kosaka, Takeo
    ANTICANCER RESEARCH, 2020, 40 (06) : 3361 - 3370
12345